About Us

Company Milestone

 

E for L Aim Public Company Limited (“the Company” or “EFORL”), formerly named Absolute Impact Public Company Limited (“AIM”) was registered on August 2005. At the beginning, the Company had the registered capital with the total of Baht 50.0 million, and its operations are to providing media production and service. After that, the Company changed the main operations into a distributor of medical devices and equipment, as importer of medical devices from manufactures, sole distributor of medical device and equipment and the medical service providers for repair and maintenance and giving medical and equipment knowledge to doctors, nurses and medical professional and patients to get the most benefits. Key Development of the Company as follows:

25 January 2022

EFORL signed a distributor agreement with Mindray Medical (Thailand) Co., Ltd., one branch of Shenzhen Mindray Bio-Medical Electronics Co., Ltd., the No.1 Medical Healthcare Company in China. The Company is appointed as a distributor of an In-Vitro Diagnostic (IVD) medical device.

8 April 2022

At the Annual General Meeting of Shareholder for the year 2022, the meeting passed resolutions as follows:

  • To increase the registered share capital of Baht 899,519,617.28 from Baht 2,998,398,708.98 to Baht 3,897,918,326.26 by issuing 11,993,594,897 ordinary shares at par value of Baht 0.075.
  • The allocation of 47 newly issued ordinary shares at the par value of Baht 0.075 per share to Mr. Preecha Nuntnarumit with the offering price at the market price with no any discounts to avoid a fraction of shares arising out from the adjusting the par value by way of reverse stock split.
  • The change of the par value of the Company’s shares by way of reverse stock split from Baht 0.075 to Baht 0.75 each.
  • The issuance and offering of Warrants No. 5 (EFORL-W5) not exceeding 799,572,990 shares to existing shareholder on a pro rata basis after changing in the par value of the Company by way of reverse stock split.
  • The issuance and offering of Warrants No. 6 (EFORL-W6) not exceeding 399,786,495 shares to existing shareholder who intends to subscribe to purchase the Warrants EFORL-W5 after changing in the par value of the Company by way of reverse stock split.
  • The increase of the Company’s registered capital to accommodate the exercise of Warrant EFORL-W5 and Warrant EFORL-W6 after changing in the par value of the Company by way of reverse stock split.

11 April 2022

EFORL changed the paid-up capital from THB 2,998,398,708.975 or number of ordinary shares 39,978,649,453 shares to THB 2,998,398,712.50 or number of ordinary shares 39,978,649,500 shares resulting from subscription of new ordinary share of Private Placement (PP) 47 shares to accommodate the changing in par value by way of the reversed stock split to avoid a fraction of shares arising out from the adjusting the par value.

21 April 2022

EFORL changed par value by the way of reverse stock split from THB 0.075 per share to THB 0.75 per share resulting in the number of registered shares and the number of paid-up capital are changed as follows:

  • Number of registered shares from 51,972,244,350 shares to 5,197,224,435 shares.
  • Number of paid-up capital from 39,978,649,500 shares to 3,997,864,950 shares.

5 July 2022

EFORL changed the paid-up capital from THB 2,998,398,712.50 or number of ordinary shares 39,978,649,500 shares to THB 2,998,398,735.00 or number of ordinary shares 3,997,864,980 shares resulting from the exercise of EFORL-W5 30 units to ordinary share 30 shares.

24 November 2022

EFORL signs an distributor agreement with Advanced Sterilization Products (Thailand) Limited appointing EFORL as a distributor for STERRAD low-temperature sterilization products using innovation in hydrogen peroxide gas plasma (HPGP) sterilization technology which helps enhance the safety of medical instruments, patients, sterile processing staff, and environment, and trusted by Healthcare institutions in Thailand and around the world.

9 February 2021

At the Extraordinary Shareholders’ Meeting No.1/2021, the meeting passed resolutions as follow:

  • To reduce the registered capital by Baht 765,052,653.075 from Baht 3,181,554,810.300 to Baht 2,416,502,157.225 by cancelling unissued registered share capital of 10,200,702,041 shares with a par value of Baht 0.075.
  • To increase the registered share capital by Baht 581,896,551.750 from Baht 2,416,502,157.225 to Baht 2,998,398,708.975 by issuing new 7,758,620,690 shares with a par value of Baht 0.075.
  • These shares were offered through a Private Placement to 3 persons at the offered price of Baht 0.0348 per share, totaling of Baht 270,000,000.

14 May 2021

At the Company’s Board of Directors Meeting No. 6/2021, the Board passed a resolution approving the sale of all investment in shares of Siam Snail Company Limited (“Siam Snail”) to other shareholders. The Company arranged for the sale of such investment on 15 July 2021, at Baht 1 per share for amount of Baht 1,020,000.

4 June 2021

The Board of Director meeting no. 7/2021 passed at resolution to sell all shares in WCI Holding Public Company Limited (“WCIH”) totaling 101,849,993 shares or 56%, at the price of Baht 0.01 per share, totaling Baht 1,018,499.93 to a third party, for which the Company received the full payment for the sale on 14 June 2021. The Company, therefore, considers the substance that the sale of investment had been completed and deconsolidated the financial statements of WCIH from its consolidated financial statements in the third quarter of 2021.

19 July 2021

At the Extraordinary Shareholders’ Meeting No.2/2021, the meeting passed resolutions as follow:

  • To amendment of the Company’s Objectives and the Memorandum of Association in Article 3 to in line with the amended Objectives of the Company from 50 clauses to 54 clauses.
  • To acknowledge the disposed all shares of WCI Holding PCL held by the Company.

28 February 2020

EFORL has been granted a patents for the computer program of the Hemodialysis Electronics Data Recording from the Department of Intellectual Property.

EFORL has been granted a patents for the computer program of the Anesthesia Electronics Data Recording from the Department of Intellectual Property.

26 March 2020

EFORL changed the paid-up capital from THB 2,416,263,899.40 or number of ordinary shares 32,216,851,992 shares to THB 2,416,501,912.80 or number of ordinary shares 32,220,025,504 shares resulting from subscription of new ordinary share (RO) 3,173,512 shares.

9 June 2020

EFORL changed the paid-up capital from THB 2,416,501,912.80 or number of ordinary shares 32,220,025,504 shares to THB 2,416,502,157.225 or number of ordinary shares 32,220,028,763 shares results of the Exercise of EFORL-W3 and EFORL-W4 3,259 shares.

14 August 2020

EFORL signs an agreement with B. Braun (Thailand) Limited to appoint EFORL as a distributor of B. Braun Avitum’s for renal care products which include Continuous Renal Replacement Therapy (CRRT) for Critical Care patients and Dialysis machines.

2 January 2019

WCIH had restructured to hold shares in subsidiary and indirect subsidiary by acquired all ordinary shares of Wuttisak Cosmetics Inter Co., Ltd., W Wellness Inter Co., Ltd. and W.S. Surgery 2014 Co., Ltd. from Wuttisak Clinic Intergroup Co., Ltd. with par value.

4 April 2019

WCIH had received the additional paid-up share capital from other existing shareholder (RO) totaling Baht 220.00 million resulting in the portion of investment in WCIH of the Company increased from 63.70% to 56.00%

5 April 2019

WCIH had restructured to hold shares in subsidiary and indirect subsidiary by acquired all ordinary shares of Wuttisak Pharmacy Inter Co., Ltd., from Wuttisak Clinic Intergroup Co., Ltd. with par value.

28 May 2019

EFORL signs agreement with GE Healthcare Pte. Ltd., Singapore, Asian Pacific Region Office of GE Healthcare (NYSE: GE) USA, to appoint EFORL as a distributor GE product of Enterprise Digital Solutions in Thailand. GE CentricityTM Cardio Enterprise. CentricityTM Cardiology Enterprise is an integrated imaging and workflow solution that bridges the gaps between cardiovascular service lines and healthcare information systems with a single point of access for patient data, waveforms, images, analysis tools and physician reports – combined with powerful end-to-end management, analytics and workflow tools. This new product will help EFORL to grow in product line of software solutions. This is a business expansion strategy and services performance strengthen EFORL to be strong in this medical industry.

5 November 2019

At the Extraordinary Shareholders Meeting of the Company No. 1/2019, the meeting passed resolutions as follow:

  • To increase the registered share capital by Baht 2,577,488,835 from Baht 3,181,554,810 to Baht 2,577,488,835 by issuing new 8,054,212,998 shares with a par value at Baht 0.075 per share.
  • To approved the allotment of new ordinary shares to existing shareholder on a pro rata basis (Right Offering) at the ratio of 4 existing shares to 1 newly issued share, at the offering price Baht 0.05 per share.

21 May 2018

At the Extraordinary Shareholders Meeting of the Company No. 1/2018, the meeting passed resolutions as follow:

  • To reduce the registered share capital of Baht 228,062,767 from Baht 1,597,429,866 to Baht 1,369,367,099 by reducing unissued registered share capital of 3,040,836,894 shares, par value at Baht 0.075 per share.
  • To increase the registered share capital of Baht 1,208,121,737 from Baht 1,369,367,099 to Baht 2,577,488,835 by issuing new 16,108,289,826 shares, par value at Baht 0.075 per share by offering to Private Placement for 5 persons at Baht 0.040 per share, totaling Baht 644,331,593.

During the year 2018, the Company received paid-up from common shares increment which offering to Private Placement from 5 persons totaling Baht 644.33 million for 16,108 million common shares.

29 June 2018

At the Extraordinary Shareholders Meeting of WCIH No. 2/2018, the meeting passed resolution as follow: 1) To change the status of WCIH from Company Limited to a Public Company Limited. (Completed on 23 July 2018) 2) To increase of WCIH’s registered share capital of Baht 870,000,020 from Baht 1,160,000,000 to Baht 2,030,000,020 by issuing ordinary shares of 87,000,002 shares at par value of Baht 10 per share. (Completed on 20 September 2018)

29 June 2018

At the Extraordinary Shareholders Meeting of WCIH No. 2/2018 has passed the resolution to approve the allotment of new ordinary shares to existing shareholder on a pro rata basis (Right Offering) at the ratio of 4 existing shares to 3 newly issued share.

14 August 2018

At the Board of Directors’ meeting of the Company No. 15/2018 has passed the resolution to subscribe for 43.65 million new ordinary shares of WCIH with a par value of Baht 10 per share. The Company paid Baht 436.50 million for their shares on quarter 3/2018.

31 December 2018

WCIH had received the additional paid-up share capital Baht 438.91 million resulting in the portion of investment in WCIH of the Company increased from 50.17% to 63.70%

30 January 2017

  • The Company has converted the warrant to purchase the Company’s common shares. (Second warrants of EFORL-W2) on 22 August 2016. The warrants 4,590,747,930 Units, representing the number of common shares in issue. 4,590,747,930 shares. Exercise price THB 0.10 per share. The Company received the proceeds from the exercise of EFORL-W2 in the amount of THB 459,074,793. The Company repaid the loan to all financial institutions.

7 April 2017

  • The Company has resolved to propose the Annual General Meeting of Shareholders for the year of 2017 to consider and approve. And approved by the shareholders.

1 May 2017

  • The Company signed a Memorandum of Understanding on the feasibility study for the development of CIS for Hemodialysis at King Chulalongkorn Memorial Hospital.

18 May 2017

  • Right to subscribe 4,596,920,476 shares with 3.0: 1.0 (existing shares: new shares). Subscription price THB 0.14 per share. Number of shares sold 2,317,528,396 shares. Outstanding 2,279,392,080 shares. A total amount received THB 324,453,975.44.

29 May 2017

  • The Company commenced trading of additional shares. 2,317,528,396 shares.

2 June 2017

  • The Company offers the warrants to purchase common shares of the Company Release 3 (EFORL-W3), which has been allocated to the shareholders for a capital increase. The offering price is THB 0.00 per unit, which can be sold in full amount 1,337,429,167 units.
  • The Company offers the warrants to purchase common shares of the Company Release 4 (EFORL-W4), which has been allocated to the shareholders for a capital increase. The offering price is THB 0.00 per unit, totaling 772,508,987 units.

30 June 2017

  • The Company sold the newly issued common shares 2,317,528,396 shares in a total amount of capital increase THB 324,453,975.44. The Company received the proceeds from the capital increase and repaid the loan to the financial institutions, with the purpose of this capital increase has already been completed.

16 December 2017

  • The Company signed a Memorandum of Cooperation “Siriraj Anesthesia Electronic Medical Record (SiA-EMR)” with the faculty of Medicine Siriraj Hospital, Mahidol University.

February 2016

  • The company was appointed by BORSAM Biomedical Instruments Co., Ltd. as the sole distributor of portable Electrocardiography (ECG) in Thailand.

March 2016

  • Siam Snail Co., Ltd. had launches the first eco-farm in Asia, located at Group 2, Ruampattana Road, Nong Chok District, Bangkok on 3.95 acres lands with the launch of a new product under the brand of “Snail 8”.

April 2016

  • Siam Snail Co., Ltd. has won the gold medal at the 44th International Exhibition of Invention of Geneva, Geneva, Switzerland.

May 2016

  • The Company has set up an affiliate named iHealth V-Care Co., Ltd. to support joint ventures and expand its network to cover ASEAN countries with iHealth Lab Inc., Silicon Valley, California, United States, In the dealership of medical devices under “iHealth” brand.

June 2016

  • Mr. Kriangsak Prateepvisut resigned from the position of Chief Financial Officer (CFO).

July 2016

  • Siam Snail Products under the “Snail 8” brand has been awarded the “Thailand Products Expo 2016” by the Premium Products of Thailand (The Pride of Thais) in Thailand Industry Expo 2016 Fair.

August 2016

  • Last exercise of warrants (EFORL-W2) 22 August 2016.

September 2016

  • The Company changed the paid-up capital from THB 690,001,012.50, numbered of common shares 9,200,013,500 shares to THB 1,034,307,107.25, number of common shares 13,790,761,730 shares from the exercise of warrants (EFORL-W2) amounting 4,590,747,930 units converted to common shares 4,590, 747,930 shares.

December 2016

  • The Board of Directors’ Meeting passed a resolution approving the liquidation and liquidation of iHealth V-care Co., Ltd. due to unclear rights to distribute products in ASEAN, this is not in accordance with the Memorandum of Understanding.

January 2015

  • WCIG assigned the Company and fifteen business consultants to evaluate the business value as of December 31, 2014 and it appeared to be that the Market Value of WCIG was Baht 5,400.0 million.

June 2015

  • The Company acquired shares of “Siam Snail Co., Ltd.” 51,000 shares; par value Baht 10 per each; equaled to 51.0 percent of paid-in capital which is Baht 1.0 million.
  • Siam Snail Co., Ltd. operated business regarding Filtrate production and distribution, especially beauty products that have Filtrate component. In addition, Siam Snail got solely license in operating the Filtrate’s production process and quality control of which was intellectual property from Chulalongkorn University Intellectual Property Institute (www.cuipi.chula.ac.th).

February 2014

  • The Executive Board of Directors’ meeting approved the appointment of Mr. Preecha Nuntnarumit as a President.
  • The headquarter was moved from the former address; 1768, 24th Floor, Thai Summit Tower, New Petchburi Road, Bangkapi Sub District, Huaykwang District, Bangkok to the new address, 184 Rajvithee Road, Bangyeekhan Sub District, Bangplad District, Bangkok 10700.

April 2014

  • The Shareholder Assembly’s meeting approved the Company to reduce the authorized capital for the amount of Baht 345,000,506.25; from Baht 1,380,002,025.-- to become Baht 1,035,001,518.75 by under value from Baht 0.10 per each to become Baht 0.075 per each.

May 2014

  • The Company signed the memorandum attached to the Contract of Management Privilege in media, activity and kiosk allocation at Chamchuri Square, dated September 29, 2014 with two months’ extension from May to October 2014.

June 2014

  • The Board of Directors approved to acquire shares from That’so Asia Corporation Co., Ltd., 360,000 shares; par value Baht 100 per each; equaled to 10.0 percent of paid-up capital which is Baht 36.0 million in total. The shares were bought from a That’so shareholder who was not related to the Company.
  • The Board of Directors approved the Public Offering of Enmo Co., Ltd., 6,999,996 shares; at five Baht per each; equaled to 100.0 percent of paid-up capital which is Baht 34,999,980 in total. The shares were offered to Mr. Kittipong Thamchutaporn who was not related to the Company.
  • The Company processed auditing and analyzing status or special checking (Due Diligence) for the purpose of acquiring shares from Wuttisak Clinic Intergroup Co., Ltd.(WCIG) and subsidiaries, as well as appointed consultants in various matters as follows:
    • 1) Financial Consultant – Advisory Plus Co., Ltd.
    • 2) Law consultant – Weerawong, Chinnavat & Peangpanor Ltd.
    • 3) Consultant for Risk Analysis on Accounting and Tax – Ernst and Young LPS.
    • 4) Freelance Financial Consultant – Capital Advantage Co., Ltd.
    • 5) Fund-raising Consultant – PrimeStreet Advisory (Thailand) Co., Ltd.

September 2014

  • The Company has the resolution to set up a new company named WCI Holding Co., Ltd. for the purpose of being shareholders in Wuttisak Clinic Intergroup Co., Ltd. (WCIG) with authorized share capital of Baht 1.0 million which segregated into three groups: 1) The Company held 60% of total shares. 2) The original founder of WCIG held 25% of total shares. 3) Solaris Fund (Solaris Asset management Co., Ltd.) held 25 % of total shares. The total number of ordinary shares is 100,000 with par value of Baht 10 while the investors have to pay Baht 25 per each accordingly.

December 2014

  • The approval votes of extraordinary meeting on November 21, 2014 was to increase paid-in capital of WCIH from Baht 1.0 million to be Baht 1,000.0 million by issuing new 99.9 million shares with par value Baht 10, while offering at Baht 25 per each; equaled to Baht 2,497.50 million in total.
  • The Company took over Wuttisak Clinic Intergroup Co., Ltd. (WCIG) via WCI Holding Co., Ltd. which is the subsidiary and held 60% of the total shares.

WCIG is in the entire aesthetic business line which concentrates on advising and providing skin treatment and body slimming under “Wuttisak Clinic”. It also has a lot of branches all over Thailand. Furthermore, WCIG serves franchise business in foreign countries (CLMV – Cambodia, Laos, Myanmar, and Vietnam). WCIG has four subsidiaries as follows:

  • 1. Wuttisak Cosmetic Inter Co., Ltd. (WCI) conducts business regarding healthy drinks (for example GlutaHealthi, Collagen VitC, Prune Berry, Click Coffee) and cosmetics.
  • 2. Wuttisak Pharmacy Inter Co., Ltd. (WPI) conducts business regarding supplementary food products.
  • 3. Wuttisak Grand Inter Co., Ltd. (WGI) doesn’t conduct any business at the moment.
  • 4. W.S. Surgery 2014 Co., Ltd. (WSS) conducts business regarding beauty service purpose.
  • December 2014: WCIG’s board of directors meeting approved new organization chart which consisted of four boards as follows:
    • 1. Board of Internal Audit and Risk Management
    • 2. Board of Administration
    • 3. Board of Medical Service and Product Development
    • 4. Board of Remuneration Seeking and Consideration
  • The criteria and responsibility of each board is appointed so that WCIG has similar standard practice like other leading firms in the future and also assures Stock Exchange, Securities and Exchange Commission, and shareholders that WCIG has the best and suitability internal control.

January 2013

  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Academic Works Dissemination Promotion Program and uNetwork.TV with King Mongkut’s University of Technology North Bangkok and Bansomdejchaopraya Rajabhat University.

May 2013

  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Academic Works Dissemination Promotion Program and uNetwork.TV with Suan Dusit Rajabhat University.

June 2013

  • The Company proceeds to increase paid-in capital from Baht 280,000,900 to be Baht 1,380,002,025 by issuing share capital 11,000,011,250 shares increase, with par value Baht 0.10 per each, equaled to Baht 1,100,001,125 to specific sectors (Private Placement - PP). And also issued 5,000,000,000 shares, at Baht 0.10 per each to the original shareholders (Rights Offering), equaled to 1,400,004,500 shares, at Baht 0.10 per each and according to Transferrable Subscription Rights proportionately to the original shares of 4,600,006,750 units.
  • The Company received paid-in capital Baht 280,000,900 to be Baht 780,000,900, sources of which came from specific sectors (Private Placement) 5,000,000,000 shares with par value Baht 0.10, and equaled to Baht 500,000,000 in total.

July 2013

  • The Company proceeded to increase the paid-in capital from Baht 780,000,900 to Baht 920,001,350 whereas the source came from increasing of share capital to the original share holder (Rights Offering) 11,000,011,250 shares with par value Baht 0.10 which equals to Baht 140,000,450 in total.

August 2013

  • The Company appointed Mr. Teerawut Pangviroonrug as a Chief Executive Officer (CEO) of the Company.
  • The Company issued the second transferable subscription rights to the initial shareholders proportionately to the original one (Rights Offering) 4,600,006,750 units without charged according to the ratio; 2 original shares: 1 subscription right unit.

September 2013

  • The Company changed a name from Absolute Impact Co., Ltd. to be E For L Aim Public Co., Ltd. together with a new logo.
  • The Company invested in acquiring shares from Spacemed Co., Ltd. who operated as a dealer for medical equipment (GE, BioSystem, Sinopharm, DIAMOND, Olympus, NK, Carestream, CareFusion) 50,000 shares, par value Baht 100 per each, which is 100% of paid-in capital, at Baht 287.83 per each, equaled to Baht 14,391,255 in total.
  • The Shareholder Assembly’s meeting approved the Company to proceed public offering common stock of Enmo Co., Ltd. (a subsidiary company) 6,999,996 shares, par value five Baht, which is 100% of paid-in capital, at Baht 4.83, equaled to Baht 33.80 million, and appointed the board of committees to sources out investors interested in online game business, on condition that the individual or juristic person who was going to buy the shares must not be related to the Company.

October 2013

  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Academic Works Dissemination Promotion Program and uNetwork.TV with Sripatum University
  • The Company invested in acquiring the share capital increase from Spacemed Co., Ltd. 45 million Baht to keep same shares proportional. Spacemed Co., Ltd. issued 450,000 of new shares, par value 100 Baht per each, and took the additional capital as a revolving fund.

November 2013

  • The Company was appointed being a distributor for medical products of "Hamilton" responsible for all over Thailand region.

December 2013

  • The Company was appointed being a dealer for medical products of “NIHON KOHDEN” responsible for all over Thailand region.
  • The Company terminated the contract of multimedia service with Siam Paragon Development Co., Ltd. and Sukhumvit City Mall Co., Ltd.
  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Shelf Media & Other Media Setting and Management Project between Home Fresh & Gourmet Market in The Mall Department Store.

November 2012

  • The Company terminated the company registration of a subsidiary named Arumy Light Co., Ltd. which operating in business consulting, public relation & marketing activity setting and consulting. The Company held 99.99 % share and the termination did not cause any effect because The Company already took over and still continued business operation with the current clients of Arumy Light Co., Ltd.

December 2012

  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Academic Works Dissemnation Promotion Program and uNetwork.TV with Rattana Bundit University and King Mongkut’s University of Technology Dhonburi.
  • The Company terminated the Memorandum of Supporting Cooperation Agreement in Multimedia Setting and Management Project, such as Sticker Wrap and Mock Up around escalator, rest room entrance, arc, and elevator facade area, with Home Fresh Mart of The Mall Department Store.
-->